par Gleich, Gerald J;Roufosse, Florence 
;Chupp, Geoffrey;Faguer, Stanislas;Walz, Bastian;Reiter, Andreas;Yancey, Steven W;Bentley, Jane J.H.;Steinfeld, Jonathan;HES Mepolizumab Study Group,
Référence The journal of allergy and clinical immunology. In practice, 9, 12, page (4431-4440.e1)
Publication Publié, 2021-12-01
;Chupp, Geoffrey;Faguer, Stanislas;Walz, Bastian;Reiter, Andreas;Yancey, Steven W;Bentley, Jane J.H.;Steinfeld, Jonathan;HES Mepolizumab Study Group, Référence The journal of allergy and clinical immunology. In practice, 9, 12, page (4431-4440.e1)
Publication Publié, 2021-12-01
Article révisé par les pairs
| Titre: |
|
| Auteur: | Gleich, Gerald J; Roufosse, Florence; Chupp, Geoffrey; Faguer, Stanislas; Walz, Bastian; Reiter, Andreas; Yancey, Steven W; Bentley, Jane J.H.; Steinfeld, Jonathan; HES Mepolizumab Study Group, |
| Informations sur la publication: | The journal of allergy and clinical immunology. In practice, 9, 12, page (4431-4440.e1) |
| Statut de publication: | Publié, 2021-12-01 |
| Sujet CREF: | Médecine pathologie humaine |
| Mots-clés: | Anti-IL-5 |
| Efficacy | |
| Flare | |
| Hypereosinophilic syndrome | |
| Mepolizumab | |
| Oral corticosteroid | |
| Safety | |
| MeSH keywords: | Adrenal Cortex Hormones |
| Antibodies, Monoclonal, Humanized | |
| Double-Blind Method | |
| Eosinophils | |
| Humans | |
| Hypereosinophilic Syndrome -- drug therapy | |
| Treatment Outcome | |
| Note générale: | SCOPUS: ar.j |
| Langue: | Anglais |
| Identificateurs: | urn:issn:E233881 |
| info:doi/10.1016/j.jaip.2021.07.050 | |
| info:pii/S2213-2198(21)00891-6 | |
| info:scp/85115013773 | |
| info:pmid/34389506 |
